ABSTRACT
Objective To explore the clinical efficacy of dendritic cell activated and cytokine induced killer cell ( DCIK ) combined chemotherapy in treatment of patients with advanced esophageal squamous carcinoma. Methods 60 patients with advanced esophageal squamous carcinoma were selected as the research subjects, they were divided into observation group (32 cases) and control group (28 cases) by random number method.The obser-vation group was given DCIK combined systemic chemotherapy treatment, while the control group was only given chemotherapy.The short-term efficacy,life quality improvement,the immune indexes and the adverse reactions were compared in the two groups 1 month after treatment.Results The short-term efficacy in the observation group was significantly better than the control group(Z=2.807,P<0.05),and the control rate was significantly higher than control group(χ2 =4.133,P<0.05).The life quality in the observation group was significantly better than the control group(Z=2.373,P<0.05),and the effective rate of the observation group was also higher than the control group (χ2 =6.459,P<0.05).The CD3+CD1+8 ,CD3+CD5+6 rates after treatment in the observation group were significantly increased than before treatment (t=7.394,P<0.05),which were significantly higher than the control group(t=-4.564,P<0.05).Conclusion DCIK cell combined chemotherapy not only can improve the immune function in patients with advanced esophageal squamous carcinoma,but also can improve the clinical symptoms and short-term life quality,which has significant clinical application value.
ABSTRACT
Objective To evaluate the relationship between resistin and hepatic fibrosis in nonalcoholic fatty liver disease (NAFLD) subjects.Methods Serum resitin and Interleukin (IL)-18's concentrations were measured in 144 subjects (70 NAFLD pa-tients and 74 healthy controls) with enzyme-linked immunosorbent assay (ELISA) and their serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting blood glucose (FBG), HbA1c, triglyceride (TG), total-cholesterol (TC), low density lip-oprotein ( LDL) , high density lipoprotein ( HDL) , homeostasis model assessment of insulin resistance ( HOMA-IR) , hyaluronic acid , IVcollagen, height, body weight, waist circumference, and hip circumference were also measured .Their waist-to-hip ratio (WHR) and body mass indes (BMI) were calculated.Results There were higher levels of systolic blood pressure (SBP), WHR, BMI, TG, ALT, AST, HOMA-IR, hyaluronic acid, IV collagen, resistin, and IL-18 in the NAFLD patients than those of the healthy controls ( P <0.05 ) .The serum resistin level was significantly and positively correlated with WHR , BMI, ALT, HOMA-IR, TG, IV collagen , and IL-18 ( r =0.231 , 0.341 , 0.223 , 0.264 , 0.213 , 0.315 , and 0.669 , P <0.05 ) .After adjustment for body fat and IL-18 , the serum resistin level was still significantly and positively correlated with ALT and IV collagen ( r =0.222 , 0.0.326 , P <0.05 ) . Conclusions Resistin might take part in the development of NAFLD insulin resistance and its pro -inflammation.
ABSTRACT
ObjectiveTo investigate the expression of autocrine motility factor receptor (AMFR)in papillary thyroid carcinoma and its relationship with clinical characteristics of this disease.Methods Real - time quantitative PCR and immunohistochemical methods were used to analyze the expression of AMFR in papillary thyroid carcinomas.ResultsThe significant differences in AMFR expression between papillary thyroid carcinoma and normal thyroid tissues were found in the levels of mRNA (6.296 ± 1.568 vs 7.913 ± 2.351,t=3.681,P=0.001 ) and protein ( 63.1％ vs 34.5 ％,x2=13.722,P ＜ 0.001 ),respectively.Immunohistochemistry analyses showed that the protein expression of AMFR in papillary thyroid carcinomas were significantly correlated with tumour size ( x2=5.209,P ＜ 0.05 ) and lymph node metastasis ( x2=4.32,P ＜ 0.05 ),and it was affected by the factors age ( x2=0.739,P=0.39 ) and gender ( x2=0.064,P=0.81 ).ConclusionsThe increased AMFR in papillary thyroid carcinoma would be a new target for cancer therapy and a new marker for prognosis.